NO20024421D0 - Polyglutaminsyre-camptotecin-konjugater og fremgangsmåte for fremstilling av disse - Google Patents
Polyglutaminsyre-camptotecin-konjugater og fremgangsmåte for fremstilling av disseInfo
- Publication number
- NO20024421D0 NO20024421D0 NO20024421A NO20024421A NO20024421D0 NO 20024421 D0 NO20024421 D0 NO 20024421D0 NO 20024421 A NO20024421 A NO 20024421A NO 20024421 A NO20024421 A NO 20024421A NO 20024421 D0 NO20024421 D0 NO 20024421D0
- Authority
- NO
- Norway
- Prior art keywords
- preparation
- polyglutamic acid
- camptothecin conjugates
- camptothecin
- conjugates
- Prior art date
Links
- 229940127093 camptothecin Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polyamides (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19042900P | 2000-03-17 | 2000-03-17 | |
PCT/US2001/008553 WO2001070275A2 (en) | 2000-03-17 | 2001-03-19 | Polyglutamic acid-camptothecin conjugates and methods of preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20024421D0 true NO20024421D0 (no) | 2002-09-16 |
NO20024421L NO20024421L (no) | 2002-11-15 |
Family
ID=22701317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20024421A NO20024421L (no) | 2000-03-17 | 2002-09-16 | Polyglutaminsyre-camptothecin-konjugater og fremgangsmÕte for fremstilling av disse |
Country Status (20)
Country | Link |
---|---|
US (1) | US20020016285A1 (no) |
EP (1) | EP1267939A2 (no) |
JP (1) | JP2003527443A (no) |
KR (1) | KR20020082888A (no) |
CN (1) | CN1429121A (no) |
AU (1) | AU2001247513A1 (no) |
BR (1) | BR0109272A (no) |
CA (1) | CA2402643A1 (no) |
CZ (1) | CZ20023330A3 (no) |
HU (1) | HUP0204562A2 (no) |
IL (1) | IL151685A0 (no) |
MX (1) | MXPA02009082A (no) |
NO (1) | NO20024421L (no) |
PL (1) | PL358335A1 (no) |
RU (1) | RU2002128610A (no) |
SI (1) | SI21172A (no) |
SK (1) | SK14822002A3 (no) |
TR (1) | TR200202194T2 (no) |
WO (1) | WO2001070275A2 (no) |
ZA (1) | ZA200207423B (no) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
PL354623A1 (en) * | 1999-10-12 | 2004-02-09 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
US20030054977A1 (en) * | 1999-10-12 | 2003-03-20 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
US20020077290A1 (en) | 2000-03-17 | 2002-06-20 | Rama Bhatt | Polyglutamic acid-camptothecin conjugates and methods of preparation |
US6629995B1 (en) * | 2000-03-31 | 2003-10-07 | Super Gen, Inc. | Camptothecin conjugates |
NZ572388A (en) * | 2002-05-17 | 2010-05-28 | Celgene Corp | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
CN1309763C (zh) * | 2002-10-31 | 2007-04-11 | 日本化药株式会社 | 喜树碱的高分子衍生物 |
EP1620544B1 (en) * | 2003-04-17 | 2018-09-19 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
US7851615B2 (en) * | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
US8017762B2 (en) * | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
US7723509B2 (en) * | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
US8796436B2 (en) | 2003-04-17 | 2014-08-05 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
JP5170741B2 (ja) | 2004-04-27 | 2013-03-27 | ウェルスタット バイオロジクス コーポレイション | ウイルスおよびカンプトテシン類を使用する癌の処置 |
US8614228B2 (en) | 2004-08-11 | 2013-12-24 | Arqule, Inc. | Quinone prodrug compositions and methods of use |
EP1877097B1 (en) | 2004-08-11 | 2012-06-20 | Arqule, Inc. | Aminoacid conjugates of beta-lapachone for tumor targeting |
KR101203475B1 (ko) * | 2004-09-22 | 2012-11-21 | 니폰 가야꾸 가부시끼가이샤 | 신규 블록 공중합체, 미셀 제제물 및 이를 유효성분으로함유하는 항암제 |
AU2006270297B2 (en) | 2005-07-14 | 2013-01-17 | Wellstat Biologics Corporation | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
ITPD20050242A1 (it) * | 2005-08-03 | 2007-02-04 | Fidia Farmaceutici | Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico |
DE602006007177D1 (de) | 2005-12-05 | 2009-07-16 | Nitto Denko Corp | Polyglutamat-aminosäure-konjugate und verfahren |
US7671067B2 (en) * | 2006-02-09 | 2010-03-02 | Enzon Pharmaceuticals, Inc. | Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin |
US7462627B2 (en) * | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
US8323669B2 (en) | 2006-03-28 | 2012-12-04 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of taxane |
EP1998809B1 (en) | 2006-03-30 | 2014-06-25 | Drais Pharmaceuticals, Inc. | Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same |
JP5181347B2 (ja) | 2006-05-18 | 2013-04-10 | 日本化薬株式会社 | ポドフィロトキシン類の高分子結合体 |
CL2007002218A1 (es) | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
JP5548364B2 (ja) * | 2006-10-03 | 2014-07-16 | 日本化薬株式会社 | レゾルシノール誘導体の高分子結合体 |
WO2008056596A1 (en) | 2006-11-06 | 2008-05-15 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
WO2008056654A1 (en) * | 2006-11-08 | 2008-05-15 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
US20080181852A1 (en) * | 2007-01-29 | 2008-07-31 | Nitto Denko Corporation | Multi-functional Drug Carriers |
KR20090108082A (ko) * | 2007-02-09 | 2009-10-14 | 엔존 파마슈티컬즈, 인코포레이티드 | 7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법 |
EP2144631A2 (en) * | 2007-04-10 | 2010-01-20 | Nitto Denko Corporation | Multi-functional polyglutamate drug carriers |
ES2532656T3 (es) | 2007-04-30 | 2015-03-30 | Arqule, Inc. | Compuestos de hidroxi sulfonato de quinona y sus usos |
CN101707869A (zh) * | 2007-05-09 | 2010-05-12 | 日东电工株式会社 | 具有多种药物的聚谷氨酸盐结合物和聚谷氨酸盐-氨基酸结合物 |
EP2155255B1 (en) * | 2007-05-09 | 2013-08-14 | Nitto Denko Corporation | Compositions that include a hydrophobic compound and a polyamino acid conjugate |
CN101730549B (zh) * | 2007-05-09 | 2015-12-09 | 日东电工株式会社 | 与铂类药物结合的聚合物 |
EP2206502B1 (en) | 2007-09-28 | 2018-09-12 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of steroid |
CN104096236A (zh) * | 2008-03-06 | 2014-10-15 | 日东电工株式会社 | 用于治疗癌症的聚合物紫杉醇结合物和方法 |
CN101977631A (zh) | 2008-03-18 | 2011-02-16 | 日本化药株式会社 | 生理活性物质的高分子量偶联物 |
EP2284209B1 (en) | 2008-05-08 | 2016-08-31 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
JP2011162569A (ja) * | 2008-05-23 | 2011-08-25 | Nano Career Kk | カンプトテシン高分子誘導体及びその用途 |
WO2010025337A1 (en) * | 2008-08-29 | 2010-03-04 | Enzon Pharmaceuticals, Inc. | Method of treating ras associated cancer |
RU2011117935A (ru) * | 2008-10-15 | 2012-11-27 | Нитто Денко Корпорейшн | Способ получения конъюгатов полиглутаматов |
JP2012506380A (ja) * | 2008-10-21 | 2012-03-15 | エンゾン ファーマシューティカルズ,インコーポレーテッド | 7−エチル−10−ヒドロキシカンプトテシンのマルチアーム型ポリマーコンジュゲートによる神経芽腫の治療 |
US8808749B2 (en) | 2009-05-15 | 2014-08-19 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of bioactive substance having hydroxy group |
EP2513133A4 (en) * | 2009-12-16 | 2014-07-02 | Nitto Denko Corp | CONTROLLED SYNTHESIS OF POLYGLUTAMIC ACID |
WO2011112733A1 (en) * | 2010-03-11 | 2011-09-15 | Nitto Denko Corporation | Carbohydrate-polyamino acid-drug conjugates |
WO2012067138A1 (ja) | 2010-11-17 | 2012-05-24 | 日本化薬株式会社 | 新規なシチジン系代謝拮抗剤の高分子誘導体 |
CN102649810A (zh) * | 2011-05-19 | 2012-08-29 | 东北林业大学 | 喜树碱衍生物、其制备方法和用途 |
JP5711378B2 (ja) | 2011-09-11 | 2015-04-30 | 日本化薬株式会社 | ブロック共重合体の製造方法 |
US9180203B2 (en) * | 2012-10-23 | 2015-11-10 | The Johns Hopkins University | Self-assembling drug amphiphiles and methods for synthesis and use |
HUE061382T2 (hu) | 2014-08-22 | 2023-06-28 | Celgene Corp | Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva |
SI3313818T1 (sl) | 2015-06-26 | 2024-03-29 | Celgene Corporation | Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev |
CN106267227A (zh) * | 2016-08-12 | 2017-01-04 | 北京蓝贝望生物医药科技股份有限公司 | 抗肿瘤药物 |
US20200030452A1 (en) * | 2016-09-30 | 2020-01-30 | IF7Cure, Inc. | Process for the Manufacture of a Tumor-Vasculature Targeting Antitumor Agent |
CN106831853B (zh) * | 2017-02-15 | 2019-02-22 | 浙江海正药业股份有限公司 | 7-乙基-10-o-叔丁基二苯基硅基喜树碱-20-o-甘氨酸盐酸盐的制备工艺 |
CN108727581A (zh) * | 2017-04-18 | 2018-11-02 | 华东师范大学 | 以苯硼酸酯为连接单元的两亲性喜树碱高分子前药及其制备方法和应用 |
JP2021095424A (ja) * | 2018-03-28 | 2021-06-24 | 持田製薬株式会社 | 抗癌剤結合アルギン酸誘導体 |
JP2023506703A (ja) | 2019-12-04 | 2023-02-20 | ダンタリ インコーポレイテッド | 治療用ナノ粒子を合成するための方法及び組成物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4356166A (en) * | 1978-12-08 | 1982-10-26 | University Of Utah | Time-release chemical delivery system |
JP3737518B2 (ja) * | 1996-03-12 | 2006-01-18 | ピージー−ティーエックスエル カンパニー, エル.ピー. | 水溶性パクリタキセルプロドラッグ |
US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
-
2001
- 2001-03-19 RU RU2002128610/15A patent/RU2002128610A/ru unknown
- 2001-03-19 PL PL01358335A patent/PL358335A1/xx not_active Application Discontinuation
- 2001-03-19 JP JP2001568471A patent/JP2003527443A/ja not_active Withdrawn
- 2001-03-19 WO PCT/US2001/008553 patent/WO2001070275A2/en not_active Application Discontinuation
- 2001-03-19 AU AU2001247513A patent/AU2001247513A1/en not_active Abandoned
- 2001-03-19 IL IL15168501A patent/IL151685A0/xx unknown
- 2001-03-19 TR TR2002/02194T patent/TR200202194T2/xx unknown
- 2001-03-19 SK SK1482-2002A patent/SK14822002A3/sk unknown
- 2001-03-19 BR BR0109272-3A patent/BR0109272A/pt active Pending
- 2001-03-19 EP EP01920466A patent/EP1267939A2/en not_active Withdrawn
- 2001-03-19 CZ CZ20023330A patent/CZ20023330A3/cs unknown
- 2001-03-19 SI SI200120021A patent/SI21172A/sl not_active IP Right Cessation
- 2001-03-19 KR KR1020027012206A patent/KR20020082888A/ko not_active Application Discontinuation
- 2001-03-19 CN CN01809441A patent/CN1429121A/zh active Pending
- 2001-03-19 CA CA002402643A patent/CA2402643A1/en not_active Abandoned
- 2001-03-19 MX MXPA02009082A patent/MXPA02009082A/es unknown
- 2001-03-19 HU HU0204562A patent/HUP0204562A2/hu unknown
- 2001-03-19 US US09/810,345 patent/US20020016285A1/en not_active Abandoned
-
2002
- 2002-09-16 NO NO20024421A patent/NO20024421L/no not_active Application Discontinuation
- 2002-09-16 ZA ZA200207423A patent/ZA200207423B/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR0109272A (pt) | 2004-06-29 |
CZ20023330A3 (cs) | 2003-02-12 |
WO2001070275A2 (en) | 2001-09-27 |
MXPA02009082A (es) | 2003-12-11 |
US20020016285A1 (en) | 2002-02-07 |
AU2001247513A1 (en) | 2001-10-03 |
RU2002128610A (ru) | 2004-03-27 |
WO2001070275A3 (en) | 2002-01-03 |
IL151685A0 (en) | 2003-04-10 |
ZA200207423B (en) | 2003-12-17 |
CA2402643A1 (en) | 2001-09-27 |
JP2003527443A (ja) | 2003-09-16 |
TR200202194T2 (tr) | 2003-01-21 |
HUP0204562A2 (hu) | 2003-04-28 |
PL358335A1 (en) | 2004-08-09 |
CN1429121A (zh) | 2003-07-09 |
NO20024421L (no) | 2002-11-15 |
EP1267939A2 (en) | 2003-01-02 |
SI21172A (sl) | 2003-10-31 |
SK14822002A3 (sk) | 2003-05-02 |
KR20020082888A (ko) | 2002-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20024421D0 (no) | Polyglutaminsyre-camptotecin-konjugater og fremgangsmåte for fremstilling av disse | |
DK1278750T3 (da) | Imidazopyrimidinderivater og triazolopyrimidinderivater | |
NO20025656L (no) | Opplöselige CTLA4 mutantmolekyler og anvendelser derav | |
DE60139930D1 (de) | Desinfizieruns- und desodorierungsverfahren | |
CY2008006I1 (el) | Παραγωγα τροπανιου χρησιμα στη θepαπευτικη | |
ID29724A (id) | Celana dalam kesehatan | |
DK1339292T3 (da) | Sammensætning og fremgangsmåde | |
DK1322597T3 (da) | Fremgangsmåde og intermediære | |
NO20025158L (no) | Lipidpreparat og anvendelse derav | |
DE60142600D1 (de) | Entwicklungsverfahren und -vorrichtung | |
DE10196082T1 (de) | FLIP-CHIP-Montageverfahren | |
DE60132068D1 (de) | Empfangsgerät | |
DE60141890D1 (de) | Biegeverfahren und biegevorrichtung | |
NO20030156D0 (no) | Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav | |
NO20025968D0 (no) | Pyridin-2-yl-aminoalkylkarbonylglycyl-<beta>-alanin og derivater derav | |
DK1263719T3 (da) | N-deacetylthiocolchin-derivater og farmaceutiske sammensætninger indeholdende disse. | |
NO20024105L (no) | Memnopeptider, fremgangsmåte for deres fremstilling og anvendelse av disse | |
NO20032821D0 (no) | Sea-trosy og beslektede fremgangsmåter | |
DK1043306T3 (da) | 3-amino-3-arylpropan-1-ol-derivater, fremstilling og anvendelse af disse | |
NO20026065D0 (no) | Prosesser for måling av dinofysistoksin og av yessotoksin | |
GB0012718D0 (en) | Conjugates of aminodrugs | |
DE60130242D1 (de) | Verbindungsmaterial und verbindungsverfahren | |
DE60118187D1 (de) | Reaktive azofarbstoffe | |
NO20023845D0 (no) | Pluraflaviner og derivater derav, fremgangsmåte for fremstilling av disse og deres anvendelse | |
NO20021143D0 (no) | Antikonvulsiv og anxiolytisk virkende 4-amino-1-aryl-1,5- dihydro-pyrrol-2-oner og fremgangsmåte for fremstilling av disse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |